Respiratory syncytial virus: desperately seeking solutions
Prescriber
; 34(4):23-26, 2023.
Article
Dans Anglais
| EMBASE | ID: covidwho-20236237
ABSTRACT
Respiratory syncytial virus (RSV) infection remains a major public health problem, especially in younger children and the elderly. But several monoclonal antibodies, antivirals and vaccines, either recently launched or in development, offer new hope for RSV prevention and treatment.Copyright © 2023 Wiley Interface Ltd.
antiviral therapy; article; asthma; bronchiolitis; common cold; coronavirus disease 2019; coughing; fever; hand washing; health service; hospital admission; hospitalization; hospitalization cost; human; Human respiratory syncytial virus; immunization; influenza; intensive care; loss of appetite; lower respiratory tract infection; lung dysplasia; malaise; meta analysis (topic); nonhuman; pneumococcal infection; pneumococcal pneumonia; pneumonia; respiratory syncytial virus infection/dt [Drug Therapy]; rhinorrhea; social distancing; sore throat; nirsevimab/dt [Drug Therapy]; palivizumab/dt [Drug Therapy]; respiratory syncytial virus vaccine/dt [Drug Therapy]; ribavirin/dt [Drug Therapy]
Texte intégral:
Disponible
Collection:
Bases de données des oragnisations internationales
Base de données:
EMBASE
Les sujets:
Vaccins
langue:
Anglais
Revue:
Prescriber
Année:
2023
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS